Abstract
Overview
RNA interference continues to emerge as a integral tool used to study the
physiological role of gene products in vivo. RNAi-based methods allow
researchers to modulate and in many cases virtually eliminate expression of a
gene of interest. Systems for delivering RNAs into cells for the purpose of
gene silencing include standard transfection technologies, both
instrument-mediated and lipid-based, as well as plasmid and viral systems for
the inducible expression of siRNAs in vivo.
Percepta' s 2010 Gene Silencing Dashboard™ dives deeply into the
characteristics and dynamics of the market for gene silencing products. This
2010 Dashboard provides a snapshot of the current market landscape that can be
compared with data from the 2008 and 2007 Gene Silencing Dashboard, providing
an ongoing story of how the market is adapting to new products, new
competitors and new sales and marketing strategies.
The Gene Silencing Dashboard™ was developed from responses to a
21-question survey completed by 281 scientists predominantly located in North
America and Europe. This Dashboard reveals key market indicators for the gene
silencing market as a whole as well as for the following methods
representing market sub-segments:
- RNAi screens using siRNA libraries (sets of 50 or more siRNAs)
- Inducing siRNAs in vivo from a plasmid or other vector in cells
- Digesting long dsRNA in vivo using dicer or other enzymes
- Expressing siRNA in vitro for delivery into cells
- Using PCS mediated siRNA expression cassettes to generate siRNAs
- Instrument mediated delivery of synthetic siRNAs into cells
- Lipid mediated delivery of synthetic siRNAs into cells
- Instrument mediated delivery of plasmids into cells for plasmid-based gene
knockdown
- Lipid mediated delivery of plasmids into cells for plasmid-based gene
knockdown
- Viral delivery of vectors into cells for vector-based gene knockdown
- Using reporter systems to track gene knockdown
Survey Methodology:
In July of 2010, Percepta fielded the Gene
Silencing Survey to a subset of the company' s panel of life scientists.
Individuals were invited by e-mail blast to click through to a webpage at
bioanalytix.com where the survey was hosted. Invitations were delivered on
July 21, 2010 and results collected through July 29. A total of 281
scientists completed the survey, of which 225 are actively engaged in
performing gene silencing experiments and 30 plan to perform gene silencing
experiments in the future. Results based on the aggregate of collected
responses are revealed in this Gene Silencing Dashboard.
Respondent Demographics
Respondents from the academic, government and commercial market segments are
well represented, with 20.8% of respondents employed in an industry setting.
73.0% of respondents are from North America, while 25.1% reside in Europe.
Junior (Lab Tech, Grad Students), mid level (Post-Doc, Lab Manager) and senior
(Professor/PI, Group Leader) scientists are well represented in the data set,
with the most cited job titles being Scientist/Senior Scientist (24.7% of
respondents) and Professor / Principle Investigator (20.8%).
A wide variety of scientific areas of specialization is also evident, led by
molecular biology (named by 28.9% of respondents as their primary area of
expertise) and cell biology (named by 17.0% of respondents). Oncology
research (9.1%) and biochemistry (7.1%) are the only other applications
named by more than 7% of respondents.
Small (1-5 scientists), medium (6-20 scientists) and large (>20 scientists)
laboratories are well represented: 36.1% of respondents work in labs where 1
to 5 people perform experiments; 51.2% in labs with 6 to 20 experimenters, and
the remaining 12.7% in labs with greater than 20 bench scientists.
60.1% of respondents indicated that 1 to 3 people in their laboratories
perform gene silencing experiments. An additional 18.5% of survey
participants revealed that 4 or 5 individuals perform gene silencing
experiments in their labs. Only 7.3% of respondents work in labs where
greater than 10 people perform gene silencing experiments.
Table of Contents
- 6. Figures and Tables
- 10. Executive Summary
- 13. Key Findings and Implications
- 18. Gene Silencing Dashboard
- 23. Gene Silencing Market Opportunity Matrix
- 25. Survey Methodology
- 27. Survey Invitation Text
- 28. Respondent Demographics
- 41. Frequency of Performance of Life Science Techniques
- 46. Frequency of Performance of Various Gene Silencing Methods
- 73. Reaction Throughput and Market Segment Growth Rates
- 80. Respondent' s Stated Price Per Reaction
- 83. Total Market Size, Market Segment Sizes and Total Market Growth
Rate
- 85. Market Shares by Segment (Share of Mention)
- 119. Customer Satisfaction And Interest In Switching Suppliers
- 125. Product Features That Influence Purchasing Decisions
- 129. Primary Downstream Applications
- 146. Desired Changes to Gene Silencing Products
- 152. Survey Questionnaire
Figures and Tables
- 30. Figure 1: Respondent' s Place of Employment
- 32. Figure 2: Respondent' s Country/Region
- 34. Figure 3: Respondent' s Job Title
- 36. Figure 4A: Respondent' s Areas of Expertise/Specialization
- 37. Figure 4B: Respondent' s Areas of Expertise/Specialization
(Molecular Biology Excluded)
- 40. Figure 5: Number of Employees in Respondent' s Laboratories
- 43. Figure 6: Percentage of Respondents Performing Various Life
Science Techniques at Least a Few Times per Year
- 49. Figure 7: Percentage of Respondents Performing RNAi/siRNA
Experiments
- 50. Figure 7A: Change in Percentage of Respondents Performing
RNAi/siRNA Experiments
- 51. Figure 8: Percentage of Respondents Performing Various Gene
Silencing Techniques at Least a Few Times per Year
- 53. Figure 9: Percentage of Respondents That Perform RNAi Screens
Using siRNA Libraries
- 54. Figure 9A: Change in Percentage of Respondents that Perform
RNAi Screens Using siRNA Libraries
- 55. Figure 10: Percentage of Respondents That Induce siRNAs in vivo
from a Plasmid or Other Vector in Cells
- 56. Figure 10A: Change in Percentage of Respondents that Induce
siRNAs in vivo from a Plasmid or Other Vector in Cells
- 57. Figure 11: Percentage of Respondents That Digest Long dsRNA in
vivo using Dicer or other Enzymes
- 58. Figure 11A: Change in Percentage of Respondents that Digest
Long ds RNA in vivo using Dicer or other Enzymes
- 59. Figure 12: Percentage of Respondents that Express siRNA in
vitro for Delivery into Cells
- 60. Figure 12A: Change in Percentage of Respondents that Express
siRNA in vitro for Delivery into Cells
- 61. Figure 13: Percentage of Respondents that Use PCR Mediated
siRNA Expression Cassettes to Generate siRNAs
- 62. Figure 13A: Change in Percentage of Respondents that Use PCR
Mediated siRNA Expression Cassettes to Generate siRNAs
- 63. Figure 14: Percentage of Respondents that Deliver Synthetic
siRNAs into Cells (Instrument Mediated)
- 64. Figure 15: Percentage of Respondents that Deliver Synthetic
siRNAs into Cells (Lipid Mediated)
- 65. Figure 16: Percentage of Respondents that Deliver Plasmids into
Cells for Plasmid Based Gene Knockdown (Instrument Mediated)
- 66. Figure 17: Percentage of Respondents that Deliver Plasmids into
Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
- 67. Figure 18: Percentage of Respondents that Deliver Viral Vectors
into Cells for Vector Based Gene Knockdown
- 68. Figure 19: Percentage of Respondents that Use a Reporter
Systems to Track Gene Knockdown
- 69. Figure 19A: Change in Percentage of Respondents that Use a
Reporter Systems to Track Gene Knockdown
- 90. Figure 20: Respondent' s Primary Supplier of Products for
Performing RNAi Screens Using siRNA Libraries
- 91. Figure 20A: Changes in Respondent' s Primary Supplier of
Products for Performing RNAi Screens Using siRNA Libraries
- 93. Figure 21: Respondent' s Primary Supplier of Products to Induce
siRNAs in vivo from a Plasmid or Other Vector in Cells
- 94. Figure 21A: Changes in Respondent' s Primary Supplier of
Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
- 96. Figure 22: Respondent' s Primary Supplier of Products to Digest
Long ds RNA in vivo using Dicer or Other Enzymes
- 97. Figure 22A: Changes in Respondent' s Primary Supplier of
Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
- 99. Figure 23: Respondent' s Primary Supplier of Products to Express
siRNA in vitro for Delivery into Cells
- 100. Figure 23A: Changes in Respondent' s Primary Supplier of
Products to Express siRNA in vitro for Delivery into Cells
- 102. Figure 24: Respondent' s Primary Supplier of PCR Mediated siRNA
Expression Cassettes to Generate siRNAs
- 103. Figure 24A: Changes in Respondent' s Primary Supplier of PCR
Mediated siRNA Expression Cassettes to Generate siRNAs
- 105. Figure 25: Respondent' s Primary Supplier of Products to
Deliver Synthetic siRNAs into Cells (Instrument Mediated)
- 107. Figure 26: Respondent' s Primary Supplier of Products to
Deliver Synthetic siRNAs into Cells (Lipid Mediated)
- 109. Figure 27: Respondent' s Primary Supplier of Products to
Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Instrument
Mediated)
- 111. Figure 28: Respondent' s Primary Supplier of Products to
Deliver Plasmids into Cells for Plasmid Based Gene Knockdown (Lipid Mediated)
- 113. Figure 29: Respondent' s Primary Supplier of Products for Viral
Delivery of Vectors into Cells for Vector Based Gene Knockdown
- 115. Figure 30: Respondent' s Primary Supplier of Reporter Systems
to Track Gene Knockdown
- 116. Figure 30A: Changes in Respondent' s Primary Supplier of
Reporter Systems to Track Gene Knockdown
- 124. Figure 31: Percentage of Respondents That Have Switched
Suppliers in the Last Six Months
- 127. Figure 32: Most Important Features of Products for Gene
Silencing Experiments
- 132. Figure 33: Respondent' s Primary Downstream Application for
RNAi Screens Using siRNA Libraries
- 133. Figure 34: Respondent' s Primary Downstream Application for
Products to Induce siRNAs in vivo from a Plasmid or Other Vector in Cells
- 134. Figure 35: Respondent' s Primary Downstream Application for
Products to Digest Long dsRNA in vivo using Dicer or Other Enzymes
- 135. Figure 36: Respondent' s Primary Downstream Application for
Products to Express siRNA in vitro for Delivery into Cells
- 136. Figure 37: Respondent' s Primary Downstream Application for PCR
Mediated siRNA Expression Cassettes to Generate siRNAs
- 137. Figure 38: Respondent' s Primary Downstream Application for
Products to Deliver Synthetic siRNAs into Cells (Instrument Mediated)
- 138. Figure 39: Respondent' s Primary Downstream Application for
Products to Deliver Synthetic siRNAs into Cells (Lipid Mediated)
- 139. Figure 40: Respondent' s Primary Downstream Application for
Products to Deliver Plasmids into Cells for Gene Knockdown (Instrument
Mediated)
- 140. Figure 41: Respondent' s Primary Downstream Application for
Products to Deliver Plasmids into Cells for Gene Knockdown (Lipid Mediated)
- 141. Figure 42: Respondent' s Primary Downstream Application for
Products to Deliver Viral Vectors into Cells for Vector Based Gene Knockdown
- 142. Figure 43: Respondent' s Primary Downstream Application for
Reporter Systems to Track Gene Knockdown
- 38. Table 1: Respondent' s Areas of Expertise/Specialization Values
for Figures 4A and 4B
- 44. Table 2: Frequency of Performance of Various Life Science
Techniques
- 45. Table 3: Frequency of Co-Performance of Various Life Science
Techniques
- 52. Table 4: Frequency of Performance of Gene Silencing Methods
- 71. Table 5: Frequency of Co-Performance of Life Science Techniques
with Gene Silencing Methods
- 72. Table 6: Frequency of Co-Performance of Gene Silencing Methods
with Life Science Techniques
- 75. Table 7: Median and Average Monthly Throughput for Gene
Silencing Products
- 76. Table 8: Percentage of Respondents Performing Various Numbers
of Gene Silencing Reactions Per Month
- 77. Table 9: Comparison to 2008 Dashboard of the Percentage of
Respondents Performing Various Numbers of Gene Silencing Reactions Per Month
- 79. Table 10: Projected Growth in the Performance of Various Gene
Silencing Techniques
- 82. Table 11: Median and Average Price Per Prep for Gene Silencing
Products
- 118. Table 12: Market Share Leaders for Gene Silencing Products
- 121. Table 13: Percentage of Respondents Satisfied with Various
Gene Silencing Products and Reasons for Dissatisfaction
- 122. Table 14: Percentage of Respondents Satisfied with Various
Gene Silencing Products: Comparison to 2008 Dashboard
- 128. Table 15: Most Important Features of Products for Gene
Silencing Experiments - Comparison to 2008 Gene Silencing Dashboard
- 143. Table 16: Respondent' s Primary Application for Various Gene
Silencing Methods
- 145. Table 17: Respondent' s Primary Application for Various Gene
Silencing Methods - Comparison to 2008 Gene Silencing Dashboard
